Both Melinta Therapeutics Inc. (NASDAQ:MLNT) and Athersys Inc. (NASDAQ:ATHX) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Melinta Therapeutics Inc.	65.17M	0.80	133.95M	-21.57	0.00
Athersys Inc.	23.95M	9.00	26.06M	-0.21	0.00

Demonstrates Melinta Therapeutics Inc. and Athersys Inc. earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 demonstrates the return on assets, net margins and return on equity of Melinta Therapeutics Inc. and Athersys Inc.

	Net Margins	Return on Equity	Return on Assets
Melinta Therapeutics Inc.	-205.54%	-69.8%	-33.4%
Athersys Inc.	-108.81%	-58.7%	-44.6%

Volatility & Risk

Melinta Therapeutics Inc.’s volatility measures that it’s 126.00% more volatile than S&P 500 due to its 2.26 beta. Athersys Inc.’s 53.00% less volatile than S&P 500 volatility due to the stock’s 0.47 beta.

Liquidity

Melinta Therapeutics Inc. has a Current Ratio of 1.3 and a Quick Ratio of 1. Competitively, Athersys Inc.’s Current Ratio is 4.6 and has 4.6 Quick Ratio. Athersys Inc.’s better ability to pay short and long-term obligations than Melinta Therapeutics Inc.

Institutional and Insider Ownership

The shares of both Melinta Therapeutics Inc. and Athersys Inc. are owned by institutional investors at 61.9% and 23.7% respectively. Melinta Therapeutics Inc.’s share held by insiders are 8.4%. On the other hand, insiders held about 2.1% of Athersys Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Melinta Therapeutics Inc.	-13.45%	22.01%	-55.22%	-77.61%	-92.23%	29.94%
Athersys Inc.	1.97%	-2.52%	-19.69%	-22.89%	15.67%	7.64%

For the past year Melinta Therapeutics Inc.’s stock price has bigger growth than Athersys Inc.

Summary

On 7 of the 10 factors Athersys Inc. beats Melinta Therapeutics Inc.

Melinta Therapeutics, Inc., an antibiotics company, is engaged in the discovery, development, and commercialization of antibiotics to overcome drug-resistant, life-threatening infections. It develops Delafloxacin, a fluoroquinolone for acute bacterial skin and skin structure infections caused by Gram-positive and Gram-negative bacteria; and Baxdela for the treatment of patients with acute bacterial skin and skin structure infections. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals and changed its name to Melinta Therapeutics, Inc. on October 7, 2013. The company was founded in 2000 and is headquartered in New Haven, Connecticut with an additional office in Lincolnshire, Illinois.

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The companyÂ’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase 2 study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase 2 clinical study for treating patients with acute myocardial infarction; and, which is in Phase 1/2 clinical study for treating patients with acute respiratory distress syndrome, as well as completed Phase 1 clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients; and 5HT2c agonists for the treatment of obesity and other conditions. The company has license and collaboration agreements with Healios K.K. and Chugai Pharmaceuticals Co., Ltd. to develop and commercialize MultiStem cell therapy for ischemic stroke; RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.